AOA Dx Announces Initial Validation of Novel Tumor Gangliosides as Promising Diagnostic Markers for Early Detection of Ovarian Cancer
AOA Dx announces initial validation of GD2 and GD3 tumor marker gangliosides as novel diagnostic markers for early detection of ovarian cancer. AOA Dx results will be presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Massachusetts Innovation Network Announces AOA Dx as the Award Recipient of Three Awards at The Eddies
AOA Dx is proud to announce the company has won the Life Science award, the People’s Choice Award, and the Robert J. Crowley award at the Massachusetts Innovation Network’ signature innovation competition, The Eddies. The Robert J. Crowley award honors those embodying the values of breakthrough thinking, passion to improve lives and unwavering commitment to the spirit of advancement.
AOA Dx Co-Founders Oriana Papin-Zoghbi and Anna Jeter Named to Inc.’s 2022 Female Founders 100 List
AOA Dx is proud to announce that co-founders Oriana Papin-Zoghbi and Anna Jeter have been named to Inc.’s 2022 Female Founders 100 List.
Inc.’s fifth annual Female Founders 100 list honors a bold group of 100 women whose innovations and ideas are shaping the world into a better place. Collectively, the 2022 honorees’ companies are estimated to be worth more than $22 billion.
AOA Dx Closes $7 million Funding Round to Bring the First Accurate Early Detection Test for Ovarian Cancer to Market
AOA Dx Inc is proud to announce that they have closed both of their seed rounds totaling a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent and other notable investors.
The funding will be used to further develop the next generation of AOA’s ovarian cancer detection technology, AKRIVIS GD™ and expand their growing team. Currently, there are no reliable ovarian cancer biomarkers that detect early stage disease.
AOA Dx was selected for MassChallenge’s 2022 US Early-Stage Cohort
AOA Dx is excited to share that the company has been selected to participate in the MassChallenge 2022 accelerator program, joining more than 200 startups. AOA Dx was one of over 1,000 other startup applications for this year’s program.
AOA Dx Announced As Finalist For The Eddies, Massachusetts Innovation Network’s Signature Innovation Competition
AOA Dx is proud to announce the company has been chosen as a finalist for Massachusetts Innovation Network’ signature innovation competition, The Eddies. Finalists will have the chance to participate in this 5-month, no-cost, no-equity innovation-support program that includes individualized mentoring, strategic guidance, leadership education, and connections to resources.
AOA Dx Welcomes Women’s Health Industry Leader Surbhi Sarna as an Independent Board Member
AOA Dx is excited to announce the appointment of Surbhi Sarna as an Independent Board Member. Sarna is most recently known for becoming Y Combinator’s first-ever partner for healthcare and biotech.
Sarna is the founder and former CEO of nVision Medical, a medical device company that to date, is the only device cleared by the FDA to collect cells from the fallopian tube, the known site of the most lethal forms of ovarian cancer. nVision Medical was acquired by Boston Scientific in 2018 for $275 million.
AOA Dx Featured in The Journal of Precision Medicine
AOA Dx Inc is proud to annouce that they were featured in “The Journal of Precision Medicine, titled “Tumor Glycolipids, a New Frontier for Early Detection and Precision Medicine in Ovarian Cancer and Other Malginancies”. The paper was authored by AOA’s Chief Scientific Officer H. Uri Saragovi, PHD, AOA’s Co-Founder and Chief Business Officer Anna Milik Jeter and Samantha A. Yee, a PhD cancidate at UT San Antonio.
AOA Dx Signs Exclusive License Agreement with Professor H. Uri Saragovi to Secure a Suite of IP Related To Early Detection of Cancer Through a Novel Quantification of Tumor Ganglioside in Liquid Biopsies
AOA Dx Inc has signed an Exclusive License Agreement with Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies.
Chief Scientific Officer of AOA Dx Has Been Awarded $650,000 by the Canadian Institute of Health Research
AOA Dx Inc is proud to announce that their Chief Scientific Officer, Prof. H. Uri Saragovi has been awarded a $650,000 CAD grant for further development of a proprietary liquid biopsy test for early stage ovarian cancer. AOA has an exclusive license agreement to the proprietary technology. In addition to serving as AOA Dx’s Chief Scientific Officer, Prof. Saragovi is the Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University